Sort   by:  
 Page size 
UnknownSetting Our Sights on Infectious Diseases.
Not available
S-EPMC6958537 | biostudies-literature
UnknownAntibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Not available
S-EPMC8927425 | biostudies-literature
UnknownFibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz Workshop.
Not available
S-EPMC8631510 | biostudies-literature
UnknownExpanded encyclopaedias of DNA elements in the human and mouse genomes.
Not available
S-EPMC7410828 | biostudies-literature
UnknownPerspectives on ENCODE.
Not available
S-EPMC7410827 | biostudies-literature
UnknownNeutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903 | biostudies-literature
UnknownGenomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission.
Not available
S-EPMC8826310 | biostudies-literature
UnknownConvalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
Not available
S-EPMC8121538 | biostudies-literature
UnknownSafety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Not available
S-EPMC11249957 | biostudies-literature
UnknownLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Not available
S-EPMC8822604 | biostudies-literature
Sort   by:  
 Page size